Brief: AB Science Announces Success Of Phase 3 AB09004 Study

AB Science SA

29/07/2021 17:15

July 29 (Reuters) - AB SCIENCE SA  ABS.PA :
    * TODAY ANNOUNCED THAT RESULTS FROM ITS PHASE 3 AB09004
STUDY ON
MILD TO MODERATE ALZHEIMER'S DISEASE HAVE BEEN PRESENTED AT
ANNUAL ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)
    * STUDY AB09004 WAS FIRST SUCCESSFUL PHASE 3 RANDOMIZED
TRIAL IN
MILD-TO-MODERATE ALZHEIMER'S DISEASE OF A DRUG TARGETING INNATE
IMMUNE CELLS OF NEUROIMMUNE SYSTEM
    * MASITINIB AT 4.5 MG/KG/DAY SHOWED SIGNIFICANT BENEFIT OVER
PLACEBO ACCORDING TO PRIMARY ANALYSIS, WITH AN ACCEPTABLE SAFETY
PROFILE
    * DATA SHOWED REDUCED LOSS OF FUNCTIONAL ABILITY IN
ACTIVITIES OF
DAILY LIVING
    * RESULTS SHOWED THAT MASITINIB CAN GENERATE A SIGNIFICANT
TREATMENT EFFECT RELATIVE TO PLACEBO IN PRIMARY ENDPOINT OF
CHANGE FROM BASELINE IN ADAS-COG, AN INSTRUMENT THAT MEASURES
EFFECT ON COGNITION AND MEMORY

Source text for Eikon:  ID:nGNX3h7D08 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))